Navigation Links
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Date:3/6/2009

ntained herein, this release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, the acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products, and the risk factors listed from time to time in Forest Laboratories' Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and any subsequent SEC filings.

About Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people's health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates.

For further information please visit the website at: www.almirall.com

        (1) WHO fact sheet 315. May 2008. Chronic obstructive pulmonary
            Disease (COPD).

        (2) Genuair is a registered trademark of Laboratorios Almirall, S.A.
            It is the proposed registered trademark for the Multiple-Dose Dry
            Powder Inhaler (MDPI) and is pending regulatory approval.


'/>"/>
SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
(Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
Breaking Medicine Technology:Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... May 11, 2011 Chimerix, Inc., a pharmaceutical ... showing that the majority of immunocompromised patients with ... lead antiviral compound, CMX001, had a > 99% ... two weeks of therapy.  These CMX001 clinical data, ...
... AUSTIN, Texas, May 11, 2011 HCB Health, one ... the nation and the leading healthcare agency in the ... campaign in the 22nd annual Manny Awards, a national ... was presented for a consumer campaign supporting Sound Surgical ...
Cached Medicine Technology:CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection 2CMX001 Shows Antiviral Activity in Immunocompromised Transplant Patients With Severe Adenovirus Infection 3HCB Health Wins Manny Award for Best Medical Device Campaign 2
(Date:4/18/2014)... Medicine scientists could lead to potential new treatments for ... scleroderma. , Fibrosis, or scarring, is a hallmark ... and lungs can lead to serious organ damage and, ... therapeutic options centers on findings made by Swati Bhattacharyya, ... role that a specific protein plays in promoting fibrosis. ...
(Date:4/17/2014)... specifically associated with the risk of a difficult-to-diagnose ... of all breast cancer cases. , The largest ... invasive lobular carcinoma, gives researchers important clues to ... breast cancer, which can be missed through screening. ... journal PloS Genetics , was co-led by ...
(Date:4/17/2014)... study published today in PLOS Pathogens , children ... is common can mount an immune response to infection ... repeated bouts of high fever and illness and partially ... The findings may help researchers develop future interventions that ... parasite. , Each year, approximately 200 million cases of ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2Health News:Building 'smart' cell-based therapies 2
... , ALEXANDRIA, Va., Oct. 7 Catholic Charities USA ... assessment and response team to American Samoa to assist ... coordinate with FEMA and other agencies in providing relief ... of the earthquake and tsunami devastation. , (Logo: ...
... Ancient Hamar Tribe Adopts Sustainable Hygiene and Water Programs ... ISLAND, Wash., Oct. 7 Northwest-based nonprofit Global Team ... grant by US Agency for International Development (USAID) to ... in Ethiopia. Since 2008, GTLI, which incubated a ...
... PRXL ) will release First Quarter Fiscal Year 2010 financial ... stock market. The announcement will be available on PAREXEL,s website ... website at www.prnewswire.com . , PAREXEL will host ... Wednesday, October 28, 2009 to discuss the results. To access ...
... This press release is available in French ... tourism in Latin America needs to be regulated to ... new study published in the journal Developing World ... marketing themselves to international health care consumers: these clinics ...
... are helping, but more is needed to stem teen obesity, ... in the United States are becoming healthier places thanks to ... still more is needed to combat teen obesity, a series ... studies, which appear in a September supplement to the ...
... The Ensign Group, Inc. (Nasdaq: ENSG ), announced ... facilities, South Valley Care Center in West Jordan, a ... Care Center in Provo, and Castle Country Care Center ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ) , "These strategic ...
Cached Medicine News:Health News:Catholic Charities USA Moves Disaster Response Team to American Samoa 2Health News:Global Team for Local Initiatives Awarded $387,000 by USAID: New Model for Indigenous Health in Ethiopia 2Health News:PAREXEL Announces Date of First Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Health News:Study examines ethical dilemmas of medical tourism 2Health News:Nutrition Still Not 'A' Grade in U.S. Schools: Studies 2Health News:The Ensign Group Acquires Three Utah Skilled Nursing Facilities 2
... system builds on the basic infrastructure ... in the system are networked to ... Windows® operating system, which monitors system ... personal computer, RoamAlert Integrity provides reporting ...
... Awarix provides an enterprise visibility ... throughput, improve caregiver effectiveness, and increase ... edge RFID location systems and geospatial ... systems to create a real time ...
MONOJECT MAGELLAN Safety Blood Collection Needle...
This is adapted to microplate or card....
Medicine Products: